

NEWSLETTER OF CLINICAL PHARMACY

St. Peter's Institute of Pharmaceutical Sciences



EDITORS

Dr. Manu Ganesh

STUDENT EDITORS

Vijay Jangidi

Kola Vandana

B. Pujitha

CONTENTS

- MISSION AND VISION
- FDA APPROVED DRUGS AUGUST-OCTOBER
- DRUG MONOGRAPH- TIRZEPTIDE
- HOSPITAL VISIT
- DEPARTMENTAL ACTIVITIES
- FACULTY ACHIEVEMENTS



TELANGANA
CHAPTER



HANAMKONDA
CHAPTER



2022 -23

PATRON



T. Jayapal Reddy,
Chairman

PRINCIPAL



Dr. Rajeshri Dhurke

EDITOR



Dr. Manu Ganesh



St. Peter's

Institute of Pharmaceutical Sciences

NBA Accredited (B.Pharmacy) | Included in UGC 2(f)
Approved by PCI | Affiliated to Kakatiya University

Mission and Vision

→ Mission

“To achieve academic excellence with integrity and create opportunities for leadership and responsibilities through ground-breaking performance in the field of Pharmaceutical Sciences by educating students about the pharmaceutical needs of the society and to advance the knowledge through research and to serve the profession and community.”

→ Vision

“St. Peter's is committed to generating, disseminating and preserving knowledge and working with pioneers of this knowledge and to be the most sought-after institute globally in the field of Pharmaceutical Sciences by creating world-class Pharmacy professionals and researchers.”

FDA APPROVED DRUGS AUGUST- OCTOBER 2024

S.NO	DRUG NAME	BRAND NAME	INDICATIONS	ADVERSE EFFECTS
1	Pimavanserin Tartrate Bulk & Pimavanserin Capsules 34 mg	NUPLAZID®	For the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.	Peripheral Edema, Confusion, Constipation, Hallucinations, QT Interval Prolongation.
2	Elagolix Sodium Bulk & Elagolix tablets 150mg and Elagolix tablets 200 mg	ORILISSA®	For the management of moderate to severe pain associated with endometriosis.	Hot Flashes, Insomnia, Bone Loss, Hepatotoxicity.
3	Brigatinib Tablets, 30mg, 90mg, and 180mg	ALUNBRIG®	Indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. Brigatinib is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.	Myalgia, Arthralgia, Hypertension, Pneumonitis, Visual Disturbances
4	Mavacamten capsules 2.5mg, 5 mg, 10mg, 15 mg	Camzyos	Mavacamten is indicated for the treatment of symptomatic (NEW York Heart Association, NYHA, class II - III) obstructive hypertrophic cardiomyopathy (oHCM) in adults patients.	Bradycardia, Hypotension, Nausea, Vomiting, Abdominal discomfort, fatigue, dizziness.

5	Ferumoxytol Bulk Drug & Ferumoxytol Injection 510 mg Elemental Iron/17mL(30mg/mL)	Feraheme TM	It is an iron replacement product indicated for the treatment of iron anemia (IDA) in adult deficiency patients: • who have intolerance to oral iron or have had unsatisfactory response to oral iron or • who have chronic kidney disease (CKD).	Rash, itching, Nausea, vomiting, diarrhea, Hypotension, dizziness,
---	--	------------------------	---	---



File No. P.17019/01/2024-DA

Dated: August 28, 2024

Monthly Drug Safety Alert

The analysis of Adverse Drug Reactions (ADRs) from the PvPI database revealed the following:

Table

S. No.	Suspected Drug	Indication	Adverse Drug Reaction
1	Metronidazole	For the treatment of amoebiasis, urogenital trichomoniasis & giardiasis.	Fixed Drug Eruption (FDE)

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADR associated with the use of above suspected drug. If, such reaction is encountered, please report to the NCC-PvPI, IPC by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>), through **PvPI Helpline No. 1800-180-3024**.



File No. P.17019/03/2024-DSA

Dated: September 25, 2024

Monthly Drug Safety Alert

The analysis of Adverse Drug Reactions (ADRs) from the PvPI database revealed the following:

Table

S. No.	Suspected Drug	Indication	Adverse Drug Reaction
1	Tetracycline	Treatment of Rocky Mountain spotted fever, typhus, Q fever, rickettsial pox, tick fever caused by Rickettsiae, respiratory tract infections caused by Mycoplasma pneumonia, Chlamydia infection, nongonococcal urethritis, chancroid, plague, tularemia, cholera, brucellosis, bartonellosis, granuloma inguinale, haemophilus and kleibsellia infections, psittacosis.	Fixed Drug Eruption

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADR associated with the use of above suspected drug. If, such reaction is encountered, please report to the NCC-PvPI, IPC by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>), through **PvPI Helpline No. 1800-180-3024**.

PRODUCT DRUG MONOGRAPH OF TIRZEPATIDE

DRUG NAME : Tirzepatide

DOSE : Injection: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen

INDICATIONS

Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use

- Tirzepatide has not been studied in patients with a history of pancreatitis [see Warnings and Precautions.
- Tirzepatide is not indicated for use in patients with type 1 diabetes mellitus

MOLECULAR WEIGHT: 4813.53 Da

MECHANISM OF ACTION:

Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucosedependent manner.



PHARMACOKINETICS

The pharmacokinetics of tirzepatide is similar between healthy subjects and patients with type 2 diabetes mellitus. Steadystate plasma tirzepatide concentrations were achieved following 4 weeks of once weekly administration. Tirzepatide exposure increases in a dose-proportional manner. **Absorption**

Following subcutaneous administration, the time to maximum plasma concentration of tirzepatide ranges from 8 to 72 hours. The mean absolute bioavailability of tirzepatide following subcutaneous administration is 80%. Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm.

Distribution

The mean apparent steady-state volume of distribution of tirzepatide following subcutaneous administration in patients with type 2 diabetes mellitus is approximately 10.3 L. Tirzepatide is highly bound to plasma albumin (99%).

Elimination

The apparent population mean clearance of tirzepatide is 0.061 L/h with an elimination half-life of approximately 5 days, enabling once-weekly dosing. Metabolism Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid moiety and amide hydrolysis. **Excretion**

The primary excretion routes of tirzepatide metabolites are via urine and feces. Intact tirzepatide is not observed in urine or feces.



C₂₂₅H₃₄₈N₄₈O₆₈

MAJOR INDICATIONS:

Type 2 Diabetes Mellitus:

- To improve blood sugar control in adults, often alongside diet and exercise.

Weight Management:

- For adults with obesity or overweight with related health conditions

DOSAGE AND ADMINISTRATION

The recommended starting dosage is 2.5 mg injected subcutaneously once weekly

- After 4 weeks, increase to 5 mg injected subcutaneously once weekly
- If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.
- The maximum dosage is 15 mg subcutaneously once weekly
- Administer once weekly at any time of day, with or without meals.
- Inject subcutaneously in the abdomen, thigh, or upper arm.
- Rotate injection sites with each dose.

SIDE EFFECTS

- Gastrointestinal issues: Nausea, vomiting, diarrhea, constipation, and stomach pain.
- Appetite changes: Reduced appetite.
- Injection site reactions: Redness, itching, or swelling.

CONTRAINDICATIONS

Tirzepatide is contraindicated in patients with:

- A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to tirzepatide or any of the excipients in Tirzepatide. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with MOUNJARO

DRUG INTERACTIONS

Tirzepatide delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications.

HOSPITAL VISIT

SPIPS at KIMS SUNSHITE HOSPITAL

On September 27th, St. Peter's Institute of Pharmaceutical Sciences, in collaboration with the Bulk Drug Manufacturers Association of India (BDMAI), organized an educational visit for PharmD students to KIMS Sunshine Hospital and CliniSync Research Organization. The visit provided students with practical exposure to hospital-based clinical practices and insights into the workings of a Contract Research Organization (CRO). The students actively participated in discussions, learning about patient care protocols, clinical trial processes, and the role of research in advancing healthcare. This experience offered valuable industry knowledge and helped bridge the gap between academic learning and professional practice.



HOSPITAL VISIT

SPIPS at KIMS SUNSHITE HOSPITAL

The participants had a great experience visiting KIMS hospital. They interacted with the staff, particularly the clinical pharmacists, who clearly explained the roles and importance of clinical pharmacists in a hospital. The pharmacists emphasized the significance of patient counselling during hospital stays and discharge, as well as continuous prescription auditing. They shared their experiences and offered suggestions for improving skills. Additionally, they provided an overview of the electronic database system used at KIMS. The importance of clinical pharmacists in correcting and avoiding medication errors was also discussed, with examples from their experiences. Key Points Learned: A clinical pharmacist plays a major role in a hospital. Clinical pharmacists are needed to counsel patients regarding their diseases, medications, etc. Prescription auditing is crucial to avoid medication errors and is a major role of clinical pharmacists. Clinical pharmacists act as a checkpoint at every step concerning patient care.



Departmental activities

August, 2024

Our Institution in association with 'International Society for Pharmacoeconomics and Outcome Research' (ISPOR) and 'Indian Pharmaceutical Association' (IPA) organised "World Organ Donation Day", on August 13, aims to raise awareness about the importance of organ donation and encourage people to pledge to donate their organs after death. It serves as a platform to educate the public about how organ donation can save lives and improve the quality of life for recipients suffering from critical illnesses.

**WORLD ORGAN
DONATION DAY,
AUGUST 13,
2024**

Creative mediums like posters, drawings, model presentations, and charts are impactful tools for spreading this vital message in college.



Departmental activities

August, 2024

Our Institution in association with 'International Society for Pharmacoeconomics and Outcome Research' (ISPOR) and 'Indian Pharmaceutical Association' (IPA) organised “National Immunization Awareness Month” (NIAM) August to highlight the importance of vaccines in protecting individuals and communities from preventable diseases. This occasion emphasizes the critical role immunization plays in public health and its contribution to building healthier futures.

Promotes Awareness: NIAM educates people about the benefits of vaccines at all stages of life—from infants to older adults.

Encourages Timely Vaccination: Staying up-to-date with recommended vaccines helps prevent outbreaks of infectious diseases.

Debunks Myths: It counters vaccine misinformation and builds public confidence in their safety and effectiveness.

NATIONAL IMMUNIZATION MONTH, AUGUST, 2024



Departmental activities

September, 2024

From September 17-23, St. Peter's Institute of Pharmaceutical Sciences, in collaboration with ISPOR India Telangana Chapter and IPA Hanamkonda Local Chapter, organized a comprehensive 6-day Value-Added Course on Pharmacovigilance. Coordinated with the IQAC and the Department of Pharmacy Practice, the course included hands-on training on the VigiFlow software and focused on various aspects of Pharmacovigilance. Topics covered included the importance of ADR reporting and the steps involved, types of ADRs, causality assessment scales, the pharmacist's role, ICH-GCP guidelines, Materiovigilance, MedDRA, Vaccine Vigilance, and the establishment of Pharmacovigilance systems in India. The course also emphasized the use of the 'Red Form' for ADR reporting. This training equipped students with valuable skills and knowledge crucial for ensuring drug safety and effective ADR monitoring

VALUE ADDED COURSE ON PHARMACO- VIGILANCE SEPTEMBER 17TH-23RD 2024




Departmental activities

September, 2024

**WORLD
PHARMACIST
DAY
SEPTEMBER 25TH,
2024**



On September 25th, St. Peter's Institute of Pharmaceutical Sciences celebrated World Pharmacist Day with engaging activities organized by the IPASF team in collaboration with the IPA Hanamkonda Local Chapter. The event included an ADR (Adverse Drug Reaction) Puzzle competition, designed to test and enhance students' understanding of Pharmacovigilance concepts and the importance of monitoring drug safety. An insightful session was conducted on the VigiFlow software, where students learned about its application in reporting and managing adverse drug reactions effectively. The event also included interactive discussions on the evolving role of pharmacists in healthcare, emphasizing their contributions to patient safety and medication management. The activities fostered active student participation, reinforcing the significance of Pharmacovigilance practices in improving public health.



Departmental activities

September, 2024

HOSPITAL VISIT AND CRO VISIT SEPTEMBER 27TH, 2024

On September 27th, St. Peter's Institute of Pharmaceutical Sciences, in collaboration with the Bulk Drug Manufacturers Association of India (BDMAI), organized an educational visit for PharmD students to KIMS Sunshine Hospital and CliniSync Research Organisation. The visit provided students with practical exposure to hospital-based clinical practices and insights into the workings of a Contract Research Organization (CRO). The students actively participated in discussions, learning about patient care protocols, clinical trial processes, and the role of research in advancing healthcare. This experience offered valuable industry knowledge and helped bridge the gap between academic learning and professional practice.




Departmental activities

OCTOBER, 2024

—
**WORLD POLIO
DAY
OCTOBER 24TH,
2024**
—

On the occasion of "World Polio Day" We IPA-SF St Peter's student chapter with the help of IPA Hanamkonda local chapter and College Management organised Awareness Campaign by visiting Anganwadi primary schools ,Karimabad , Warangal.



World Polio Day, observed annually on October 24th, serves as a crucial reminder of the fight against polio, a debilitating disease that can cause lifelong paralysis.

The significance of World Polio Day lies in raising awareness about the importance of vaccination and maintaining global eradication efforts. Together, we can finish the fight against this disease and make history by eradicating polio for good.

Departmental activities

OCTOBER, 2024

On the Eve of World Stroke Day, IPASF St. Peter's Hanamkonda chapter organized an awareness campaign at Rohini SuperSpeciality Hospital Where Pharm.D students, utilising their Clinical Pharmacy knowledge, led a meaningful awareness campaign. Through dedicated counseling sessions, we engaged with patients and caregivers, offering guidance on stroke paralysis, diet, lifestyle changes, and therapy essentials. Every effort in spreading awareness strengthens our collective fight against stroke—empowering patients and building a healthier tomorrow."

***WORLD STROKE
DAY OCTOBER,
2024***



Departmental activities



November, 2024

"On the Eve of World Diabetes Day, with the theme "Breaking Barriers, Bridging Gaps," IPASF St. Peter's Hanamkonda chapter organized impactful activities to raise awareness about diabetes. We provided effective diabetes information, focusing on lifestyle management, the importance of medication adherence, and the role of dietary management in controlling blood sugar levels. Special emphasis was placed on lifestyle modifications, including regular physical activity, balanced nutrition, and blood glucose monitoring.

Interactive displays featured puzzles, comic designs, charts, and riddles to engage attendees and reinforce key messages on diabetes care. Exercise demonstrations highlighted the role of physical activity in diabetes control, while a creative Rangoli competition brought an artistic touch to the awareness campaign.

We're proud to have shared educational leaflets, provided counseling on medication, diet, and lifestyle modifications, and made a meaningful difference in the lives of diabetic patients and their caregivers. Special thanks to the active participation of all attendees for their enthusiasm and engagement.

**WORLD
DIABETES
DAY
NOVEMBER,
2024**



FACULTY ACHIEVEMENTS

82nd FIP world congress of pharmacy and pharmaceutical sciences. Capetown South Africa

St. Peter's Institute of Pharmaceutical Sciences at World Congress of FIP with over 140 countries. Jayapal Reddy Thumma, our chairman, representing as Director of IACP and Council member of FIP from IACP, deliver Talk on Emotional Intelligence - Critical Thinking for a Pharmacist aiming towards Leadership and Entrepreneurial roles. Dr. D Praveen, HOD Pharmacy Practice, has delivered a talk and being awarded with Tom Hoek Award being presented during Inaugural of World Congress.



FACULTY ACHIEVEMENTS

National conference on automation, IT and Recent advancements in pharmaceutical sciences (ICAAPS 2024) between 26th and 27th September 2024 at PSG college of Pharmacy, Coimbatore, Tamil Nadu

Dr. D Praveen, HOD Pharmacy Practice, delivered a talk as an invited Speaker at PSG College of Pharmacy's National Conference on Automation, IT and Recent advancements in Pharmaceutical sciences "(ICAAPS 2024) between 26th and 27th September 2024. Combatore on Artificial Intelligence in Clinical Pharmacy Practice and Education - Global Perspective



FACULTY ACHIEVEMENTS

33rd Singapore Pharmacy Congress 5-6th October 2024

St. Peter's Institute of Pharmaceutical Sciences at 33rd Singapore Pharmaceutical Congress. Jayapal Reddy Thumma, our chairman and Dr. D Praveen, Our HOD Pharmacy Practice, as speakers.



STUDENT ACHIEVEMENTS

33rd Singapore Pharmacy Congress 5-6th October 2024

Our student, Sai Sudha, PharmD
V year, has presented a poster at
33rd Singapore Pharmacy
Congress



FACULTY ACHIEVEMENTS

FAPA 2024 Seoul Republic of Korea 29th October - 2nd November 2024

"30th Congress of the Federation of Asian Pharmaceutical Associations"

St Peters Institute of Pharmaceutical Sciences is represented by our Principal Dr. Rajeshri Wakode Dhurke, Dr Ranadheer Chowdary Puvvada and Ms Manusri Naredla who also presented research posters on respective works.

